載入中
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
一般交易時段
US$6.05
−US$0.08 · -1.31%
盤中時間採用ET。市場資料可能有所延遲。
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
日內區間
目前US$6.05
52週區間
目前US$6.05
盤中時間採用ET。市場資料可能有所延遲。
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
日內區間
目前US$6.05
52週區間
目前US$6.05
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 644萬 USD | 2962.1萬 USD | 4680.3萬 USD | 1.41億 USD | 2.35億 USD |
| 銷貨成本 | 55.6萬 USD | 1556.1萬 USD | 396.2萬 USD | 2028萬 USD | 4.49億 USD |
| 毛利 | 588.4萬 USD | 1406萬 USD | 4284.1萬 USD | 1.2億 USD | −2.14億 USD |
| 研究與開發 | 2351.7萬 USD | 9569.2萬 USD | 2.66億 USD | 2.97億 USD | 3.87億 USD |
| 銷售、一般及管理費用 | 2770.9萬 USD | 4933萬 USD | 8648.3萬 USD | 1.25億 USD | — |
| 營業費用 | 5177.9萬 USD | 1.64億 USD | 3.66億 USD | 4.21億 USD | 7464.7萬 USD |
| 利息收入 | 294.3萬 USD | 529.6萬 USD | 759.4萬 USD | 759.6萬 USD | — |
| 利息支出 | 875.9萬 USD | 824.7萬 USD | 809.5萬 USD | 144萬 USD | 107.5萬 USD |
| 折舊和攤銷 | 74.8萬 USD | 269.2萬 USD | 993萬 USD | 1060.4萬 USD | 1480.9萬 USD |
| 營業利益 | −4589.5萬 USD | −1.5億 USD | −3.23億 USD | −3.01億 USD | −2.89億 USD |
| 淨利 | 1.83億 USD | −4757.9萬 USD | −2.84億 USD | −2.94億 USD | −2.9億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$28.00
上漲空間 362.81%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年6月17日 | 1:25 | — | — |
已生效 2025年6月17日
1:25
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
